Cargando…
Patients’ experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative study
BACKGROUND: There is increasing evidence suggesting that open-label placebo (OLP) is an effective treatment for several medical conditions defined by self-report. However, little is known about patients’ experiences with OLP, and no studies have directly compared patients’ experiences in double-blin...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815135/ https://www.ncbi.nlm.nih.gov/pubmed/35120572 http://dx.doi.org/10.1186/s40359-022-00731-w |
_version_ | 1784645220984422400 |
---|---|
author | Haas, Julia W. Ongaro, Giulio Jacobson, Eric Conboy, Lisa A. Nee, Judy Iturrino, Johanna Rangan, Vikram Lembo, Anthony Kaptchuk, Ted J. Ballou, Sarah |
author_facet | Haas, Julia W. Ongaro, Giulio Jacobson, Eric Conboy, Lisa A. Nee, Judy Iturrino, Johanna Rangan, Vikram Lembo, Anthony Kaptchuk, Ted J. Ballou, Sarah |
author_sort | Haas, Julia W. |
collection | PubMed |
description | BACKGROUND: There is increasing evidence suggesting that open-label placebo (OLP) is an effective treatment for several medical conditions defined by self-report. However, little is known about patients’ experiences with OLP, and no studies have directly compared patients’ experiences in double-blind placebo (DBP) conditions. METHODS: This study was nested in a large randomized-controlled trial comparing the effects of OLP and DBP treatments in individuals with irritable bowel syndrome (IBS). We randomly selected 33 participants for interviews concerning their experiences in the parent trial. The data were qualitatively analyzed using an iterative immersion/crystallization approach. We then compared the qualitative interview data to the quantitative IBS severity data assessed during the parent trial, using a mixed methods approach. RESULTS: Two prominent interview themes were identified: (1) the participants’ feelings about their treatment allocation and (2) their reflections about the treatment. Both OLP and DBP participants mentioned hope and curiosity as major feelings driving them to engage with their treatment. However, while DBP participants tended to be more enthusiastic about their allocation, OLP participants were more ambivalent. Furthermore, OLP participants reflected more on their treatment, often involving noticeable cognitive and emotional processes of self-reflection. They offered a variety of explanations for their symptom improvement and were significantly less likely to attribute it to the treatment itself than DBP participants (Χ(2) [3] = 8.28; p = .041). Similarly, the participants’ retrospective narratives of symptom improvement were significantly correlated with their corresponding quantitative IBS severity scores only in DBP (p’s ≤ .006) but not in OLP (p’s ≥ .637). CONCLUSION: OLP and DBP participants share feelings of hope, uncertainty and curiosity but differ in the extent of conscious reflection. The counter-intuitive OLP prompts more self-examination, ambivalent feelings and active engagement compared to DBP. At the same time, OLP participants are more reluctant to attribute symptom improvement to their treatment. Our findings substantially add to the emerging picture of factors that distinguish OLP and DBP and their potential mechanisms. |
format | Online Article Text |
id | pubmed-8815135 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88151352022-02-07 Patients’ experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative study Haas, Julia W. Ongaro, Giulio Jacobson, Eric Conboy, Lisa A. Nee, Judy Iturrino, Johanna Rangan, Vikram Lembo, Anthony Kaptchuk, Ted J. Ballou, Sarah BMC Psychol Research BACKGROUND: There is increasing evidence suggesting that open-label placebo (OLP) is an effective treatment for several medical conditions defined by self-report. However, little is known about patients’ experiences with OLP, and no studies have directly compared patients’ experiences in double-blind placebo (DBP) conditions. METHODS: This study was nested in a large randomized-controlled trial comparing the effects of OLP and DBP treatments in individuals with irritable bowel syndrome (IBS). We randomly selected 33 participants for interviews concerning their experiences in the parent trial. The data were qualitatively analyzed using an iterative immersion/crystallization approach. We then compared the qualitative interview data to the quantitative IBS severity data assessed during the parent trial, using a mixed methods approach. RESULTS: Two prominent interview themes were identified: (1) the participants’ feelings about their treatment allocation and (2) their reflections about the treatment. Both OLP and DBP participants mentioned hope and curiosity as major feelings driving them to engage with their treatment. However, while DBP participants tended to be more enthusiastic about their allocation, OLP participants were more ambivalent. Furthermore, OLP participants reflected more on their treatment, often involving noticeable cognitive and emotional processes of self-reflection. They offered a variety of explanations for their symptom improvement and were significantly less likely to attribute it to the treatment itself than DBP participants (Χ(2) [3] = 8.28; p = .041). Similarly, the participants’ retrospective narratives of symptom improvement were significantly correlated with their corresponding quantitative IBS severity scores only in DBP (p’s ≤ .006) but not in OLP (p’s ≥ .637). CONCLUSION: OLP and DBP participants share feelings of hope, uncertainty and curiosity but differ in the extent of conscious reflection. The counter-intuitive OLP prompts more self-examination, ambivalent feelings and active engagement compared to DBP. At the same time, OLP participants are more reluctant to attribute symptom improvement to their treatment. Our findings substantially add to the emerging picture of factors that distinguish OLP and DBP and their potential mechanisms. BioMed Central 2022-02-04 /pmc/articles/PMC8815135/ /pubmed/35120572 http://dx.doi.org/10.1186/s40359-022-00731-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Haas, Julia W. Ongaro, Giulio Jacobson, Eric Conboy, Lisa A. Nee, Judy Iturrino, Johanna Rangan, Vikram Lembo, Anthony Kaptchuk, Ted J. Ballou, Sarah Patients’ experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative study |
title | Patients’ experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative study |
title_full | Patients’ experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative study |
title_fullStr | Patients’ experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative study |
title_full_unstemmed | Patients’ experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative study |
title_short | Patients’ experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative study |
title_sort | patients’ experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815135/ https://www.ncbi.nlm.nih.gov/pubmed/35120572 http://dx.doi.org/10.1186/s40359-022-00731-w |
work_keys_str_mv | AT haasjuliaw patientsexperiencestreatedwithopenlabelplaceboversusdoubleblindplaceboamixedmethodsqualitativestudy AT ongarogiulio patientsexperiencestreatedwithopenlabelplaceboversusdoubleblindplaceboamixedmethodsqualitativestudy AT jacobsoneric patientsexperiencestreatedwithopenlabelplaceboversusdoubleblindplaceboamixedmethodsqualitativestudy AT conboylisaa patientsexperiencestreatedwithopenlabelplaceboversusdoubleblindplaceboamixedmethodsqualitativestudy AT neejudy patientsexperiencestreatedwithopenlabelplaceboversusdoubleblindplaceboamixedmethodsqualitativestudy AT iturrinojohanna patientsexperiencestreatedwithopenlabelplaceboversusdoubleblindplaceboamixedmethodsqualitativestudy AT ranganvikram patientsexperiencestreatedwithopenlabelplaceboversusdoubleblindplaceboamixedmethodsqualitativestudy AT lemboanthony patientsexperiencestreatedwithopenlabelplaceboversusdoubleblindplaceboamixedmethodsqualitativestudy AT kaptchuktedj patientsexperiencestreatedwithopenlabelplaceboversusdoubleblindplaceboamixedmethodsqualitativestudy AT ballousarah patientsexperiencestreatedwithopenlabelplaceboversusdoubleblindplaceboamixedmethodsqualitativestudy |